Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/98533
標題: 影響多中心型淋巴瘤患犬在治療後長期存活之因子之回溯研究
A Retrospective Study of Factors Affecting Long-term Survival in Dogs with Multicentric Lymphomas after Treatment
作者: 廖志杰
Chih-Chieh Liao
關鍵字: 
多中心型淋巴瘤
存活時間
疾病穩定間期
dogs
multicentric lymphoma
survival time
progression-free interval
引用: Abbo, A.H., Lucroy, M.D., 2007. Assessment of anemia as an independent predictor of response to chemotherapy and survival in dogs with lymphoma: 96 cases (1993-2006). Journal of the American Veterinary Medical Association 231, 1836-1842. Appelbaum, F.R., Sale, G.E., Storb, R., Charrier, K., Deeg, H.J., Graham, T., Wulff, J.C., 1984. Phenotyping of canine lymphoma with monoclonal antibodies directed at cell surface antigens: classification, morphology, clinical presentation and response to chemotherapy. Hematological Oncology 2, 151-168. Aresu, L., Arico, A., Ferraresso, S., Martini, V., Comazzi, S., Riondato, F., Giantin, M., Dacasto, M., Guadagnin, E., Frayssinet, P., Rouquet, N., Drigo, M., Marconato, L., 2014. Minimal residual disease detection by flow cytometry and PARR in lymph node, peripheral blood and bone marrow, following treatment of dogs with diffuse large B-cell lymphoma. Veterinary Journal 200, 318-324. Baldwin, K., Bartges, J., Buffington, T., Freeman, L.M., Grabow, M., Legred, J., Ostwald, D., Jr., 2010. AAHA nutritional assessment guidelines for dogs and cats. Journal of the American Animal Hospital Association 46, 285-296. Bauer, N.B., Zervos, D., Moritz, A., 2007. Argyrophilic nucleolar organizing regions and Ki67 equally reflect proliferation in fine needle aspirates of normal, hyperplastic, inflamed, and neoplastic canine lymph nodes (n= 101). Journal of Veterinary Internal Medicine 21, 928-935. Beaver, L.M., Strottner, G., Klein, M.K., 2010. Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006–2008). Journal of the American Veterinary Medical Association 237, 1052-1055. Bell, R., Cotter, S., Lillquist, A., Sallan, S., McCaffrey, R., 1984. Characterization of glucocorticoid receptors in animal lymphoblastic disease: correlation with response to single-agent glucocorticoid treatment. Blood 63, 380-383. Blackwood, L., German, A., Stell, A., O'neill, T., 2004. Multicentric lymphoma in a dog after cyclosporine therapy. Journal of Small Animal Practice 45, 259-262. Burnett, R., Vernau, W., Modiano, J., Olver, C., Moore, P., Avery, A., 2003. Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. Veterinary Pathology 40, 32-41. Burton, J., Garrett‐Mayer, E., Thamm, D., 2013. Evaluation of a 15‐week CHOP protocol for the treatment of canine multicentric lymphoma. Veterinary and Comparative Oncology 11, 306-315. Carter, R., Harris, C., Withrow, S., Valli, V., Susaneck, S., 1987. Chemotherapy of canine lymphoma with histopathological correlation: doxorubicin alone compared to COP as first treatment regimen. Journal of the American Animal Hospital Association 23, 587-596. Carter, R., Valli, V., Lumsden, J., 1986. The cytology, histology and prevalence of cell types in canine lymphoma classified according to the National Cancer Institute Working Formulation. Canadian Journal of Veterinary Research 50, 154. Cartwright, R., Brincker, H., Carli, P., Clayden, D., Coebergh, J., Jack, A., McNally, R., Morgan, G., De Sanjose, S., Tumino, R., 1999. The rise in incidence of lymphomas in Europe 1985–1992. European Journal of Cancer 35, 627-633. Chun, R., Garrett, L.D., Vail, D.M., 2000. Evaluation of a High‐Dose Chemotherapy Protocol with No Maintenance Therapy for Dogs with Lymphoma. Journal of Veterinary Internal Medicine 14, 120-124. Cotter, S., 1983. Treatment of lymphoma and leukemia with cyclophosphamide, vincristine, and prednisone. 1. Treatment of Dogs. Journal of the American Animal Hospital Association 19, 159-165. Day, M., 1996. Serial monitoring of clinical, haematological and immunological parameters in canine autoimmune haemolytic anaemia. Journal of Small Animal Practice 37, 523-534. Dobson, J., Samuel, S., Milstein, H., Rogers, K., Wood, J., 2002. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. Journal of Small Animal Practice 43, 240-246. Dobson, J.M., Blackwood, L.B., McInnes, E.F., Bostock, D.E., Nicholls, P., Hoather, T.M., Tom, B.D., 2001. Prognostic variables in canine multicentric lymphosarcoma. Journal of Small Animal Practice 42, 377-384. Dorn, C., Taylor, D., Hibbard, H., 1967. Epizootiologic characteristics of canine and feline leukemia and lymphoma. American Journal of Veterinary Research 28, 993. Dorn, C., Taylor, D.O., Schneider, R., 1970. The Epidemiology of Canine Leukemia and Lymphoma1, In: Comparative Leukemia Research 1969. Karger Publishers, pp. 403-415. Edwards, D., Henley, W., Harding, E., Dobson, J., Wood, J., 2003. Breed incidence of lymphoma in a UK population of insured dogs. Veterinary and Comparative Oncology 1, 200-206. Flood‐Knapik, K., Durham, A., Gregor, T., Sánchez, M., Durney, M., Sorenmo, K., 2013. Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma. Veterinary and Comparative Oncology 11, 272-286. Fournel-Fleury, C., Magnol, J., Chabanne, L., Ghernati, I., Marchal, T., Bonnefond, C., Bryon, P., Felman, P., 1997. Growth fractions in canine non-Hodgkin's lymphomas as determined in situ by the expression of the Ki-67 antigen. Journal of Comparative Pathology 117, 61-72. Fournel-Fleury, C., Ponce, F., Felman, P., Blavier, A., Bonnefont, C., Chabanne, L., Marchal, T., Cadore, J., Goy-Thollot, I., Ledieu, D., 2002. Canine T-cell lymphomas: a morphological, immunological, and clinical study of 46 new cases. Veterinary Pathology 39, 92-109. Freeman, L., Becvarova, I., Cave, N., MacKay, C., Nguyen, P., Rama, B., Takashima, G., Tiffin, R., Tsjimoto, H., van Beukelen, P., 2011. WSAVA Nutritional Assessment Guidelines. Journal of Small Animal Practice 52, 385-396. Garrett, L.D., Thamm, D.H., Chun, R., Dudley, R., Vail, D.M., 2002. Evaluation of a 6‐month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 16, 704-709. Gavazza, A., Presciuttini, S., Barale, R., Lubas, G., Gugliucci, B., 2001. Association between canine malignant lymphoma, living in industrial areas, and use of chemicals by dog owners. Journal of Veterinary Internal Medicine 15, 190-195. Greenlee, P.G., Filippa, D.A., Quimby, F.W., Patnaik, A.K., Calvano, S.E., Matus, R.E., Kimmel, M., Hurvitz, A.I., Lieberman, P.H., 1990. Lymphomas in dogs a morphologic, immunologic, and clinical study. Cancer 66, 480-490. Guija de Arespacochaga, A., Schwendenwein, I., Weissenbock, H., 2007. Retrospective study of 82 cases of canine lymphoma in Austria based on the Working Formulation and immunophenotyping. Journal of Comparative Pathology 136, 186-192. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K., Cleary, M.L., Delsol, G., De Wolf-Peeters, C., Falini, B., Gatter, K.C., et al., 1994. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84, 1361-1392. Higginbotham, M.L., McCaw, D.L., Roush, J.K., Nietfeld, J.C., Wilkerson, M.J., Reeds, K., Burr, D., 2013. Intermittent single-agent doxorubicin for the treatment of canine B-cell lymphoma. Journal of the American Animal Hospital Association 49, 357-362. Hipple, A., Colitz, C., Mauldin, G., Mauldin, G., Cho, D., 2003. Telomerase activity and related properties of normal canine lymph node and canine lymphoma. Veterinary and Comparative Oncology 1, 140-151. Hosoya, K., Kisseberth, W.C., Lord, L.K., Alvarez, F.J., Lara-Garcia, A., Kosarek, C.E., London, C.A., Couto, C.G., 2007. Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma. Journal of Veterinary Internal Medicine 21, 1355-1363. Howlader, N., Noone, A., Krapcho, M., Neyman, N., Aminou, R., Altekruse, S., Kosary, C., Ruhl, J., Tatalovich, Z., Cho, H., 2012. SEER cancer statistics review, 1975–2009 (vintage 2009 populations). Bethesda, MD: National Cancer Institute. Lung Cancer. Jacobs, R., Messick, J., Valli, V., 2002. Tumors of the hemolymphatic system. Tumors in Domestic Animals, Fourth Edition, 119-198. Jagielski, D., Lechowski, R., HOFFMANN‐JAGIELSKA, M., Winiarczyk, S., 2002. A retrospective study of the incidence and prognostic factors of multicentric lymphoma in dogs (1998–2000). Transboundary and Emerging Diseases 49, 419-424. Kaiser, C.I., Fidel, J.L., Roos, M., Kaser-Hotz, B., 2007. Reevaluation of the University of Wisconsin 2-year protocol for treating canine lymphosarcoma. Journal of the American Animal Hospital Association 43, 85-92. Kaiser, H., 1981. Animal neoplasms: A systemic review. Neoplasms: Comparative Pathology in Animals, Plants, and Man. Baltimore: Williams and Wilkins., 47-751. Keller, E.T., MacEwen, E.G., Rosenthal, R.C., Helfand, S.C., Fox, L.E., 1993. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. Journal of Veterinary Internal Medicine 7, 289-295. Kiupel, M., Bostock, D., Bergmann, V., 1998. The prognostic significance of AgNOR counts and PCNA-positive cell counts in canine malignant lymphomas. Journal of Comparative Pathology 119, 407-418. Legendre, A.M., 2007. Treatment of dogs with lymphoma: a work in progress. Journal of Veterinary Internal Medicine 21, 1166-1167. Lennert, K., Feller, A.C., 1992. Histopathology of Non-Hodgkin's Lymphomas : Based on the Updated Kiel Classification. Springer Berlin Heidelberg, Berlin, Heidelberg. Lori, J.C., Stein, T.J., Thamm, D.H., 2010. Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study. Veterinary and Comparative Oncology 8, 188-195. MacEwen, E.G., Patnaik, A.K., Wilkins, R.J., 1977. Diagnosis and treatment of canine hematopoietic neoplasms. The Veterinary Clinics of North America 7, 105-118. Madewell, B., Feldman, B., 1980. Characterization of anemias associated with neoplasia in small animals. Journal of the American Veterinary Medical Association 176, 419-425. Madewell, B., Theilen, G., 1987. Hematopoietic neoplasms, sarcomas and related conditions. Veterinary Cancer Medicine 2, 101-104. Marconato, L., Leo, C., Girelli, R., Salvi, S., Abramo, F., Bettini, G., Comazzi, S., Nardi, P., Albanese, F., Zini, E., 2009. Association between waste management and cancer in companion animals. Journal of Veterinary Internal Medicine 23, 564-569. Marconato, L., Stefanello, D., Valenti, P., Bonfanti, U., Comazzi, S., Roccabianca, P., Caniatti, M., Romanelli, G., Massari, F., Zini, E., 2011. Predictors of long-term survival in dogs with high-grade multicentric lymphoma. Journal of the American Veterinary Medical Association 238, 480-485. Miller, A.G., Morley, P.S., Rao, S., Avery, A.C., Lana, S.E., Olver, C.S., 2009. Anemia is associated with decreased survival time in dogs with lymphoma. Journal of Veterinary Internal Medicine 23, 116-122. Mutsaers, A.J., Glickman, N.W., DeNicola, D.B., Widmer, W.R., Bonney, P.L., Hahn, K.A., Knapp, D.W., 2002. Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs. Journal of the American Veterinary Medical Association 220, 1813-1817. Owen, L.N., 1980. TNM classification of tumours in domestic animals. World Health Organization, Geneva. Pastor, M., Chalvet‐Monfray, K., Marchal, T., Keck, G., Magnol, J., Fournel‐Fleury, C., Ponce, F., 2009. Genetic and environmental risk indicators in canine non‐Hodgkin's lymphomas: Breed associations and geographic distribution of 608 cases diagnosed throughout France over 1 year. Journal of Veterinary Internal Medicine 23, 301-310. Piek, C., Putteman, G., Teske, E., 1999. Evaluation of the results of a L‐asparaginase‐based continuous chemotherapy protocol versus a short doxorubicin‐based induction chemotherapy protocol in dogs with malignant lymphoma. Veterinary Quarterly 21, 44-49. Poggi, A., Miniscalco, B., Morello, E., Comazzi, S., Gelain, M., Aresu, L., Riondato, F., 2015. Flow cytometric evaluation of ki67 for the determination of malignancy grade in canine lymphoma. Veterinary and Comparative Oncology 13, 475-480. Ponce, F., Marchal, T., Magnol, J., Turinelli, V., Ledieu, D., Bonnefont, C., Pastor, M., Delignette, M., Fournel-Fleury, C., 2010. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Veterinary Pathology 47, 414-433. Postorino, N., Susaneck, S., Withrow, S., Macy, D., Harris, C., 1989. Single agent therapy with adriamycin for canine lymphosarcoma. Journal of the American Animal Hospital Association 25, 221-225. Priester, W.A., McKay, F.W., 1980. The occurrence of tumors in domestic animals. National Cancer Institute Monograph, 1-210. Rao, S., Lana, S., Eickhoff, J., Marcus, E., Avery, P., Morley, P., Avery, A., 2011. Class II major histocompatibility complex expression and cell size independently predict survival in canine B‐cell lymphoma. Journal of Veterinary Internal Medicine 25, 1097-1105. Rebhun, R., Kent, M., Borrofka, S., Frazier, S., Skorupski, K., Rodriguez, C., 2011. CHOP chemotherapy for the treatment of canine multicentric T‐cell lymphoma. Veterinary and Comparative Oncology 9, 38-44. Reif, J.S., Lower, K.S., Ogilvie, G.K., 1995. Residential exposure to magnetic fields and risk of canine lymphoma. American Journal of Epidemiology 141, 352-359. Romano, F.R., Heinze, C.R., Barber, L.G., Mason, J.B., Freeman, L.M., 2016. Association between Body Condition Score and Cancer Prognosis in Dogs with Lymphoma and Osteosarcoma. Journal of Veterinary Internal Medicine 30, 1179-1186. Rosenberg, S., 1982. The non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49, 2112-2135. Ruslander, D.A., Gebhard, D.H., Tompkins, M.B., Grindem, C.B., Page, R.L., 1997. Immunophenotypic characterization of canine lymphoproliferative disorders. In Vivo 11, 169-172. Sambrook, J., Fritsch, E.F., Maniatis, T., 1989. Molecular cloning: a laboratory manual. Cold spring harbor laboratory press. Santoro, D., Marsella, R., Hernandez, J., 2007. Investigation on the association between atopic dermatitis and the development of mycosis fungoides in dogs: A retrospective case‐control study. Veterinary Dermatology 18, 101-106. Sato, M., Yamazaki, J., Goto‐Koshino, Y., Takahashi, M., Fujino, Y., Ohno, K., Tsujimoto, H., 2011. Increase in minimal residual disease in peripheral blood before clinical relapse in dogs with lymphoma that achieved complete remission after chemotherapy. Journal of Veterinary Internal Medicine 25, 292-296. Sato, M., Yamzaki, J., Goto-Koshino, Y., Takahashi, M., Fujino, Y., Ohno, K., Tsujimoto, H., 2013. The prognostic significance of minimal residual disease in the early phases of chemotherapy in dogs with high-grade B-cell lymphoma. Veterinary Journal 195, 319-324. Siedlecki, C.T., Kass, P.H., Jakubiak, M.J., Dank, G., Lyons, J., Kent, M.S., 2006. Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma. The Canadian Veterinary Journal 47, 52-59. Simon, D., Nolte, I., Eberle, N., Abbrederis, N., Killich, M., Hirschberger, J., 2006. Treatment of Dogs with Lymphoma Using a 12‐Week, Maintenance‐Free Combination Chemotherapy Protocol. Journal of Veterinary Internal Medicine 20, 948-954. Smith, L.K., Cidlowski, J.A., 2010. Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes, In: Progress in brain research. Elsevier, pp. 1-30. Sorenmo, K., Overley, B., Krick, E., Ferrara, T., LaBlanc, A., Shofer, F., 2010. Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases. Veterinary and Comparative Oncology 8, 196-208. Squire, R.A., Bush, M., Melby, E.C., Neeley, L.M., Yarbrough, B., 1973. Clinical and pathologic study of canine lymphoma: clinical staging, cell classification, and therapy. Journal of the National Cancer Institute 51, 565-574. Stefanello, D., Valenti, P., Zini, E., Comazzi, S., Gelain, M., Roccabianca, P., Avallone, G., Caniatti, M., Marconato, L., 2011. Splenic marginal zone lymphoma in 5 dogs (2001–2008). Journal of Veterinary Internal Medicine 25, 90-93. Takashima-Uebelhoer, B.B., Barber, L.G., Zagarins, S.E., Procter-Gray, E., Gollenberg, A.L., Moore, A.S., Bertone-Johnson, E.R., 2012. Household chemical exposures and the risk of canine malignant lymphoma, a model for human non-Hodgkin's lymphoma. Environmental Research 112, 171-176. Teske, E., De Vos, J., Egberink, H., Vos, J., 1994a. Clustering in canine malignant lymphoma. Veterinary Quarterly 16, 134-136. Teske, E., Van Heerde, P., Rutteman, G.R., Kurzman, I.D., Moore, P., MacEwen, E., 1994b. Prognostic factors for treatment of malignant lymphoma in dogs. Journal of the American Veterinary Medical Association 205, 1722-1728. Thamm, D.H., Grunerud, K.K., Rose, B.J., Vail, D.M., Bailey, S.M., 2013. DNA repair deficiency as a susceptibility marker for spontaneous lymphoma in golden retriever dogs: a case-control study. PLoS One 8, e69192. Thomas, R., Smith, K., Ostrander, E., Galibert, F., Breen, M., 2003. Chromosome aberrations in canine multicentric lymphomas detected with comparative genomic hybridisation and a panel of single locus probes. British Journal of Cancer 89, 1530. Torres de la Riva, G., Hart, B.L., Farver, T.B., Oberbauer, A.M., Messam, L.L., Willits, N., Hart, L.A., 2013. Neutering dogs: effects on joint disorders and cancers in golden retrievers. PLoS One 8, e55937. Vail, D., Kisseberth, W., Obradovich, J., Moore, F., London, C., MacEwen, E., Ritter, M., 1996. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma. Experimental Hematology 24, 807-815. Vail, D.M., 2005. Hematopoietic tumors. Elsevier Saunders, St. Louis, Mo. Vail, D.M., Michels, G.M., Khanna, C., Selting, K.A., London, C.A., 2010. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document. Veterinary and Comparative Oncology 8, 28-37. Vail, D.M., Pinkerton, M.E., Young, K.M., 2013. Hematopoietic Tumors In: Withrow and MacEwen's Small Animal Clinical Oncology, 5th ed. W.B. Saunders, Saint Louis, pp. 608-678. Valerius, K.D., Ogilvie, G.K., Mallinckrodt, C.H., Getzy, D.M., 1997. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). Journal of the American Veterinary Medical Association 210, 512-516. Valli, V., Kass, P., Myint, M.S., Scott, F., 2013. Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival. Veterinary Pathology 50, 738-748. Valli, V., Myint, M.S., Barthel, A., Bienzle, D., Caswell, J., Colbatzky, F., Durham, A., Ehrhart, E., Johnson, Y., Jones, C., 2011. Classification of canine malignant lymphomas according to the World Health Organization criteria. Veterinary Pathology 48, 198-211. Valli, V., Vernau, W., De Lorimier, L.-p., Graham, P., Moore, P., 2006. Canine indolent nodular lymphoma. Veterinary Pathology 43, 241-256. Valli, V.E., Pathology, A.F.I.o., Pathology, A.R.o., Oncology, W.C.C.f.W.R.o.C., 2002. Histological Classification of Hematopoietic Tumors of Domestic Animals. Armed Forces Institute of Pathology. Vaughan, A., Johnson, J.L., Williams, L.E., 2007. Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol. Journal of Veterinary Internal Medicine 21, 1332-1339. Vezzali, E., Parodi, A., Marcato, P., Bettini, G., 2010. Histopathologic classification of 171 cases of canine and feline non‐Hodgkin lymphoma according to the WHO. Veterinary and Comparative Oncology 8, 38-49. Villamil, J.A., Henry, C.J., Hahn, A.W., Bryan, J.N., Tyler, J.W., Caldwell, C.W., 2009. Hormonal and sex impact on the epidemiology of canine lymphoma. Journal of Cancer Epidemiology 2009. Wang, S.L., Lee, J.J., Liao, A.T., 2015. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma. Veterinary Journal 205, 69-73. Wang, S.L., Lee, J.J., Liao, A.T., 2016. Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma. The Canadian Veterinary Journal 57, 271-276. Wilkerson, M., Dolce, K., Koopman, T., Shuman, W., Chun, R., Garrett, L., Barber, L., Avery, A., 2005. Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules. Veterinary Immunology and Immunopathology 106, 179-196. Yamazaki, J., Takahashi, M., Setoguchi, A., Fujino, Y., Ohno, K., Tsujimoto, H., 2010. Monitoring of Minimal Residual Disease (MRD) after Multidrug Chemotherapy and Its Correlation to Outcome in Dogs with Lymphoma: A Proof‐of‐Concept Pilot Study. Journal of Veterinary Internal Medicine 24, 897-903. Yau, P., Dhand, N.K., Thomson, P.C., Taylor, R.M., 2017. Retrospective study on the occurrence of canine lymphoma and associated breed risks in a population of dogs in NSW (2001-2009). Aust Vet J 95, 149-155. Zandvliet, M., 2016. Canine lymphoma: a review. Veterinary Quarterly 36, 76-104. Zink, M.C., Farhoody, P., Elser, S.E., Ruffini, L.D., Gibbons, T.A., Rieger, R.H., 2014. Evaluation of the risk and age of onset of cancer and behavioral disorders in gonadectomized Vizslas. Journal of the American Veterinary Medical Association 244, 309-319.
摘要: 淋巴瘤是犬最常見的血液來源腫瘤,雖然大部分患犬對於治療有反應,但是僅有少數能達到長期存活。本研究目的為探討影響多中心型淋巴瘤患犬經治療後的總存活時間(OST)或疾病穩定間期(PFI)之臨床和病理學因子;其中總存活時間定義為發現淋巴結腫大到死亡的時間;疾病穩定間期為從治療後完全或部分緩解到疾病進展或因淋巴瘤死亡的時間。本研究共納入82隻確診為多中心型淋巴瘤且接受治療的患犬。單變因分析結果顯示B細胞淋巴瘤、接受單獨doxorubicin或是CHOP(cyclophosphamide、doxorubicin、vincristine和prednisolone)療程、療程中體重上升等因子的患犬有明顯較長的OST。此外,臨床亞期a、B細胞淋巴瘤、療程中出現白血球減少、達到腫瘤完全緩解、確診淋巴瘤時無貧血等因子的患犬有顯著較長的PFI。由多變因分析結果可知,臨床亞期a、B細胞淋巴瘤、治療中體重上升等因子的病犬有較長的總生存時間,但是具有非B和非T細胞淋巴瘤、只用類固醇治療、淋巴瘤診斷時有貧血等因子則有較短的PFI。除此之外,在CHOP療程組別與單純使用doxorubicin治療組別中OST或PFI較長的患犬,與前4次化療中出現完全或部分緩解、化療藥施打次數等因子有相關。總結來說,本篇研究顯示接受CHOP與DXR療程治療的狗有較好的預後,除此之外,臨床亞期a、B細胞淋巴瘤、腫瘤在施打化療藥的前4次有完全或是部分緩解、淋巴瘤診斷時無貧血、治療中有白血球低下、治療中體重上升等因子有較長的OST、PFI,與有較高的一年以上存活率,並且可將在存活時間長的病犬之臨床或病理因子運用於臨床上。
Lymphoma is the most common hematopoietic tumor in dogs; although most patients had response to the treatment, few of them could achieve longer survival after treatment. The aim of this study was to investigate the clinico-pathologic variables which have potential positive effects to overall survival time (OST), which defined as time from the lymphadenopathy first noted to death, and progression-free interval (PFI), which defined as the time from the identification of complete remission or partial remission until disease progression or lymphoma-associated death, in dogs with multicentric lymphomas after treatment. Eighty-two dogs that were diagnosed as multicentric lymphoma with treatments were enrolled. Univariate analysis revealed that dogs with B-cell phenotype, treated with single-agent doxorubicin or CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), and body-weight gain during treatment had significantly longer OST. Furthermore, dogs with substage a, B-cell phenotype, leukopenia during treatment, complete response, and absence of anemia at diagnosis were associated with significantly longer PFI. By multivariate analysis, substage a, B-cell phenotype, and body-weight gain were the positive factors of longer OST; however, the factors of shorter PFI were non-B/non-T phenotype, single-agent prednisolone treatment and presence of anemia at diagnosis. Additionally, dogs with longer OST or PFI in the single-agent doxorubicin and CHOP treatment groups revealed significant association with complete response (CR) or partial response (PR) during first 4 times of chemotherapy and number of chemotherapy injection times by univariate and multivariate analyses. In conclusion, this study found that dogs administered with CHOP and DXR treatment had better prognosis; moreover, substage a, B-cell phenotype, CR or PR during first 4 times of chemotherapy, no anemia at diagnosis, leukopenia during treatment, and gaining weight during treatment were related to longer OST or PFI and associated to equal to or longer than one year OST. These prognostic factors of the dogs with longer survival would be useful in practice.
URI: http://hdl.handle.net/11455/98533
文章公開時間: 2018-08-16
Appears in Collections:獸醫學系所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.